UK markets close in 7 hours 51 minutes

Oxford BioMedica plc (OXB.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
307.50+7.50 (+2.50%)
As of 08:24AM BST. Market open.
Currency in GBp

Valuation measures4

Market cap (intra-day) 300.00M
Enterprise value 307.74M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.24
Price/book (mrq)4.05
Enterprise value/revenue 3.44
Enterprise value/EBITDA -2.04

Trading information

Stock price history

Beta (5Y monthly) 1.03
52-week change 3-30.84%
S&P500 52-week change 321.33%
52-week high 3474.50
52-week low 3164.29
50-day moving average 3200.52
200-day moving average 3235.42

Share statistics

Avg vol (3-month) 3339.74k
Avg vol (10-day) 3437.22k
Shares outstanding 5100M
Implied shares outstanding 6100M
Float 864.26M
% held by insiders 116.18%
% held by institutions 158.08%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:50
Last split date 330 May 2018

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -175.89%
Operating margin (ttm)-74.78%

Management effectiveness

Return on assets (ttm)-15.08%
Return on equity (ttm)-117.29%

Income statement

Revenue (ttm)89.54M
Revenue per share (ttm)0.93
Quarterly revenue growth (yoy)-38.80%
Gross profit (ttm)N/A
EBITDA -70.09M
Net income avi to common (ttm)-157.49M
Diluted EPS (ttm)-1.63
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)103.72M
Total cash per share (mrq)1.07
Total debt (mrq)111.46M
Total debt/equity (mrq)143.20%
Current ratio (mrq)3.19
Book value per share (mrq)0.76

Cash flow statement

Operating cash flow (ttm)-28.52M
Levered free cash flow (ttm)-18.34M